{Reference Type}: Journal Article
{Title}: Blockade of Fibroblast YAP Attenuates Cardiac Fibrosis and Dysfunction Through MRTF-A Inhibition.
{Author}: Francisco J;Zhang Y;Jeong JI;Mizushima W;Ikeda S;Ivessa A;Oka S;Zhai P;Tallquist MD;Del Re DP;
{Journal}: JACC Basic Transl Sci
{Volume}: 5
{Issue}: 9
{Year}: Sep 2020
{Factor}: 9.531
{DOI}: 10.1016/j.jacbts.2020.07.009
{Abstract}: Fibrotic remodeling of the heart in response to injury contributes to heart failure, yet therapies to treat fibrosis remain elusive. Yes-associated protein (YAP) is activated in cardiac fibroblasts by myocardial infarction, and genetic inhibition of fibroblast YAP attenuates myocardial infarction-induced cardiac dysfunction and fibrosis. YAP promotes myofibroblast differentiation and associated extracellular matrix gene expression through engagement of TEA domain transcription factor 1 and subsequent de novo expression of myocardin-related transcription factor A. Thus, fibroblast YAP is a promising therapeutic target to prevent fibrotic remodeling and heart failure.